Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-ExPEL
2020-001075-32Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab, trifluridine + tipiracil in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Institut für Klinische Krebsforschung. Started May 2020; status: completed.
02
Drugs
ramucirumabtrifluridine + tipiracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2020-001075-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001075-32.